Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjuvant atezolizumab versus placebo after nephrectomy in high-risk renal cell carcinoma
MOH_2017-06-05_000346Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Atezolizumab with Placebo (2 arms). Primary endpoints: Efficacy of adjuvant atezolizumab and Safety of adjuvant atezolizumab. Started Jan 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2017-06-05_000346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-05_000346.